This is an article about portfolio company, Tetra Therapeutics.
After years of raising millions in capital and federal grant funding for Tetra Therapeutics Inc. — which was developing a new drug that could potentially treat Alzheimer’s disease and a form of autism — Mark Gurney in 2020 finally found the big money he needed to get to the end.
The Grand Rapids-based Tetra Therapeutics last spring sold to Japanese pharmaceutical company Shionogi & Co. Ltd. in a deal that could reach $500 million. Under the agreement, Shionogi & Co. acquired Tetra and its portfolio of drug compounds for treating Alzheimer’s disease, Fragile X syndrome, and other brain disorders associated with cognitive or memory conditions
View source version on mibiz.com: https://mibiz.com/sections/health-care/tetra-therapeutics-shionogi-deal-builds-resources-of-large-pharmaceutical-company